Cheap supplies of a groundbreaking twice-yearly HIV prevention jab will be available in many poorer countries within two years, funders have promised.
Lenacapavir will cost $40 (£30) a patient a year in 120 low- and middle-income countries from 2027, under two agreements with generic drug...